We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > PML

News List

NeoImmuneTech Announces First Patient Dosed in the Pilot Study of NT-I7 (efineptakin alfa) in Progressive Multifocal Leukoencephalopathy americanpharmaceuticalreview
May 28, 2021
NeoImmuneTech, Inc., a clinical-stage T cell-focused biopharmaceutical company, announced that the first patient has been dosed in the pilot study evaluating NT-I7 (efineptakin alfa), a novel long-acting human IL-7, in progressive multifocal ...
NeoImmuneTech receives FDA orphan drug designation for NT-I7 to treat Progressive Multifocal Leukoencephalopathy pharmaceutical-business-review
June 17, 2020
NeoImmuneTech, a clinical-stage T cell-focused biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to NeoImmuneTech’s NT-I7 (efineptakin alfa) ...